Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
2019 3
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues.
Bonk S, Kluth M, Hube-Magg C, Polonski A, Soekeland G, Makropidi-Fraune G, Möller-Koop C, Witt M, Luebke AM, Hinsch A, Burandt E, Steurer S, Clauditz TS, Schlomm T, Perez D, Graefen M, Heinzer H, Huland H, Izbicki JR, Wilczak W, Minner S, Sauter G, Simon R. Bonk S, et al. Oncotarget. 2019 Sep 10;10(52):5439-5453. doi: 10.18632/oncotarget.27145. eCollection 2019 Sep 10. Oncotarget. 2019. PMID: 31534629 Free PMC article.
Upregulation of SPDEF is associated with poor prognosis in prostate cancer.
Meiners J, Schulz K, Möller K, Höflmayer D, Burdelski C, Hube-Magg C, Simon R, Göbel C, Hinsch A, Reiswich V, Weidemann S, Izbicki JR, Sauter G, Jacobsen F, Möller-Koop C, Mandelkow T, Blessin NC, Lutz F, Viehweger F, Lennartz M, Fraune C, Heinzer H, Minner S, Bonk S, Huland H, Graefen M, Schlomm T, Büscheck F. Meiners J, et al. Oncol Lett. 2019 Nov;18(5):5107-5118. doi: 10.3892/ol.2019.10885. Epub 2019 Sep 19. Oncol Lett. 2019. PMID: 31612022 Free PMC article.
High RSF1 protein expression is an independent prognostic feature in prostate cancer.
Höflmayer D, Hamuda M, Schroeder C, Hube-Magg C, Simon R, Göbel C, Hinsch A, Weidemann S, Möller K, Izbicki JR, Jacobsen F, Mandelkow T, Blessin NC, Lutz F, Viehweger F, Sauter G, Burandt E, Lebok P, Lennartz M, Fraune C, Minner S, Bonk S, Huland H, Graefen M, Schlomm T, Büscheck F. Höflmayer D, et al. Acta Oncol. 2020 Mar;59(3):268-273. doi: 10.1080/0284186X.2019.1686537. Epub 2019 Nov 5. Acta Oncol. 2020. PMID: 31687881
Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients.
Büscheck F, Sulimankhil M, Melling N, Höflmayer D, Hube-Magg C, Simon R, Göbel C, Hinsch A, Weidemann S, Izbicki JR, Jacobsen F, Mandelkow T, Blessin NC, Möller-Koop C, Lutz F, Viehweger F, Möller K, Sauter G, Lennartz M, Burandt E, Lebok P, Minner S, Bonk S, Huland H, Graefen M, Schlomm T, Fraune C. Büscheck F, et al. Cancer Med. 2020 Feb;9(4):1409-1418. doi: 10.1002/cam4.2773. Epub 2020 Jan 1. Cancer Med. 2020. PMID: 31893572 Free PMC article.
High B7-H3 expression is linked to increased risk of prostate cancer progression.
Bonk S, Tasdelen P, Kluth M, Hube-Magg C, Makrypidi-Fraune G, Möller K, Höflmayer D, Dwertmann Rico S, Büscheck F, Minner S, Heinzer H, Graefen M, Hinsch A, Luebke AM, Dum D, Uhlig R, Schlomm T, Sauter G, Simon R, Weidemann SA. Bonk S, et al. Pathol Int. 2020 Aug 10. doi: 10.1111/pin.12999. Online ahead of print. Pathol Int. 2020. PMID: 32776718
Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.
Bonk S, Kluth M, Jansen K, Hube-Magg C, Makrypidi-Fraune G, Höflmayer D, Weidemann S, Möller K, Uhlig R, Büscheck F, Luebke AM, Burandt E, Clauditz TS, Steurer S, Schlomm T, Huland H, Heinzer H, Sauter G, Simon R, Dum D. Bonk S, et al. Prostate. 2020 Sep;80(13):1097-1107. doi: 10.1002/pros.24038. Epub 2020 Jul 6. Prostate. 2020. PMID: 32628300
Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers.
Möller K, Wecker AL, Höflmayer D, Fraune C, Makrypidi-Fraune G, Hube-Magg C, Kluth M, Steurer S, Clauditz TS, Wilczak W, Simon R, Sauter G, Huland H, Heinzer H, Haese A, Schlomm T, Weidemann S, Luebke AM, Minner S, Bernreuther C, Bonk S, Marx A. Möller K, et al. Virchows Arch. 2020 May 16. doi: 10.1007/s00428-020-02834-4. Online ahead of print. Virchows Arch. 2020. PMID: 32417965